Results 161 to 170 of about 1,470 (198)
Some of the next articles are maybe not open access.
Efgartigimod hilft bei Immunthrombozytopenie
HämostaseologieDie primäre Immunthrombozytopenie (ITP) ist eine erworbene Autoimmunerkrankung durch Autoantikörper gegen thrombozytäre Antigene und gekennzeichnet durch eine isolierte Thrombozytopenie. Efgartigimod bindet den Fc-Rezeptor kompetitiv und bewirkt einen Abbau und die Reduktion zirkulierender IgG-Autoantikörper. In der Phase-3-ADVANCE-IV-Studie
openaire +2 more sources
Efgartigimod: A Review in Generalised Myasthenia Gravis
DrugsEfgartigimod (Vyvgart®; Vyvgart® Hytrulo) is a neonatal fragment crystallizable receptor (FcRn) antagonist indicated for the treatment of generalised myasthenia gravis (gMG) in adults who are acetylcholine receptor (AChR) antibody positive (Ab+). Efgartigimod is approved for both intravenous (IV) and subcutaneous (SC) use. In a pivotal phase III trial,
openaire +2 more sources
Canadian Journal of Health Technologies
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source
Efgartigimod as a novel FcRn inhibitor for autoimmune disease
Neurological SciencesImmunoglobulin G (IgG) autoantibodies can lead to the formation of autoimmune diseases through Fab and/or Fc-mediated interactions with host molecules as well as activated T cells. The neonatal Fc receptor (FcRn) binds at acidic pH IgG and albumin, and the mechanism for prolonging serum IgG half-life is making IgG re-entry into circulation by prompting
Yun Yang +4 more
openaire +2 more sources
Efgartigimod: Potential Impact on IVIG Therapy
The Journal of Allergy and Clinical Immunology: In Practice, 2022Jeffrey G, Demain, Francisco A, Bonilla
openaire +2 more sources
A systematic review of efgartigimod as an effective treatment for myasthenic crisis
Naunyn-Schmiedeberg's Archives of PharmacologyEfgartigimod is a neonatal Fc receptor (FcRn) inhibitor that primarily diminishes antibody levels by inhibiting antibody (IgG) reabsorption and is noted for its rapid onset of action and low immunogenicity. Currently, efgartigimod is approved for the treatment of anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG ...
Ping, Tang +3 more
openaire +2 more sources
Efgartigimod improves triple-negative myasthenia gravis
Neurological Sciences, 2023Rita Frangiamore +5 more
openaire +2 more sources
Efgartigimod successful in immune thrombocytopenia
Medicom Conference Report ASH 2022, 2023openaire +1 more source
Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience
Expert Review of Clinical Immunology, 2022Jessica Barreto Ribeiro Dos Santos +2 more
exaly